Drug intelligence / Profile preview

GSK3888130B

Development stage: Phase 1
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

GSK3888130B is a monoclonal antibody developed by GSK targeting interleukin 7 (IL-7). It acts as an IL-7 modulator and is designed to block the activation of immune cells that damage myelin sheaths in diseases such as multiple sclerosis. By inhibiting IL-7 signaling, it aims to reduce immune-mediated nerve cell damage. The drug has been evaluated in first-in-human studies for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants via both intravenous and subcutaneous administration. Its primary indications under investigation are multiple sclerosis and ulcerative colitis[3][5].

Targets

IL7 (IL-7)

Beyond the preview

Go deeper on GSK3888130B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK3888130B.

Explore the full profile